Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole vs Fluconazole in High-risk Leukopenic Patients
NCT00811928Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of posaconazole in invasive fungal infection (IFI) (2 arms), sponsored by Merck & Co. Primary endpoint: Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period up to 12 Weeks. Started Nov 2008; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00811928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811928.